Skip to main content
. 2020 Sep 16;44(5):1875–1884. doi: 10.3892/or.2020.7770

Figure 5.

Figure 5.

Downregulation of SERPINE1 decreases the tumorigenic capacity of PTX-resistant BC cells in vivo. (A) Image revealing the appearance of tumors from mice that were inoculated with MDA-MB-231/PTX cells with or without SERPINE1 knockdown. (B) Quantification of tumor volumes at the end of the in vivo tumorigenic assays. **P<0.01. SERPINE1, serine protease inhibitor, clade E member 1; PTX, paclitaxel; BC, breast cancer.